triheptanoin

Action and Spectrum

Drug Interaction

Adverse Reaction

Frequency Defined  

>10%  

Diarrhea (44%)  

Nausea (14%)  

Vomiting (44%)  

Abdominal pain (60%)  

Black Box Warning

Contraindication / Caution

Pregnancy / Lactation

Pregnancy warnings:     

US FDA pregnancy category: N/A 

Lactation:   

Excreted into human milk is unknown  

Pregnancy Categories:         

Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.    

Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.   

Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.     

Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.     

Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.     

Category N: There is no data available for the drug under this category 

Pharmacology

Adminstartion

Patient Information Leaflet

Patient information leaflet 

Generic Name: triheptanoin  

Why do we use triheptanoin? 

triheptanoin is a medication that is used as a source of calories and fatty acids for people with a condition called long-chain fatty acid oxidation disorders (LC-FAODs). These are rare genetic disorders that affect the body’s ability to break down and use long-chain fatty acids, which are a type of fat that is important for energy production and other functions in the body.  

People with LC-FAODs may have difficulty getting enough energy and nutrients from their diet, which can lead to serious health problems. Symptoms of LC-FAODs may include weakness, fatigue, trouble breathing, abnormal heart rhythms, and developmental delays. LC-FAODs can be caused by mutations in any of several different genes that are involved in the metabolism of long-chain fats.